1. Diminished suppressive potency of primary Treg clones from IPEXA384T patients.
Diminished suppressive potency of primary Treg clones from IPEXA384T patients. (A) FOXP3 and CD25 expression in CD4+ cells of IPEXA384T patients and age- and sex-matched controls ex vivo. The FOXP3 MFI levels of CD25+FOXP3+ cells were determined in independent assessments and were normalized to the corresponding healthy controls. (B to E) Pools of single cell–derived clones of FOXP3+ and FOXP3− CD4+ T cells were generated from IPEX patients (shown as IPEX 1 and 2) and their corresponding controls (Control 1 and 2). (B) FOXP3 and CD25 expression at the harvest of the clones. (C) Cytokine production assessed by flow cytometry. (D) Proliferation of individual T cell clones in the absence of exogenous rhIL-2. cpm, counts per minute. (E) Suppression of proliferation of allogeneic CD4+CD25− T cells. Clone sample sizes: IPEX 1: FOXP3+ = 5, FOXP3− = 14; Control 1: FOXP3+ = 17, FOXP3− = 19; IPEX 2: FOXP3+ = 110, FOXP3− = 10, Control 2: FOXP3+ = 70, FOXP3− = 41. Data are presented as individual clones with line at median ± interquartile range. All data sets were compared with one-way nonparametric ANOVA (P < ) and followed by Dunn’s posttest.
Khalid Bin Dhuban et al. Sci. Immunol. 2017;2:eaai9297
Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.